This combination treatment ICG-001/anti-PD-1 effectively suppresses HCC growth in mice by upregulating the expression of CCL5, and promoting the infiltration of immune cells such as DC and CD8 + T cells in the tumour microenvironment [88]. This evidence concerns the gene CCL5 and neoplasm.